Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-11-2014 | Original Article – Cancer Research

LASP-1 promotes tumor proliferation and metastasis and is an independent unfavorable prognostic factor in gastric cancer

Published in: Journal of Cancer Research and Clinical Oncology | Issue 11/2014

Abstract

Purpose

The LIM and SH3 protein 1 (LASP-1) is a focal adhesion protein, and its expression has been reported to be increased in many malignant tumors. However, the role of LASP-1 in gastric cancer is still unknown. The aim of this study was to determine the relationship of LASP-1 expression with the progression and prognosis of gastric cancer.

Methods

Expression of LASP-1 was evaluated in gastric cancer tissues and cell lines by immunohistochemistry and Western blot analysis. The relationship between LASP-1 expression and clinicopathological characteristics was analyzed. Using RNA interference, the effects of LASP-1 on cell proliferation, migration and invasion were investigated in gastric cancer cell lines both in vitro and in vivo.

Results

The LASP-1 was overexpressed in gastric cancer tissues and cell lines. LASP-1 expression was significantly associated with tumor size, invasive depth, TNM stage, lymph node metastasis and p53 expression (all P < 0.05). Multivariate survival analysis showed that LASP-1 expression was recognized as an independent prognostic factor of patient’s survival. Knockdown of LASP-1 inhibited cell proliferation, migration and invasion in vitro as well as tumorigenesis and metastasis in vivo.

Conclusions

Our study showed that LASP-1, overexpressed in gastric cancer and associated with poor prognosis, plays an important role in the growth and metastasis of gastric cancer.

Chen DL, Zeng ZL, Yang J et al (2013) L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer. J Hematol Oncol 6:43PubMedCrossRefPubMedCentral

Chew CS, Parente JJ, Zhou C et al (1998) Lasp-1 is a regulated phosphoprotein within the cAMP signaling pathway in the gastric parietal cell. Am J Physiol 275:C56–C67PubMed

Chew CS, Parente JJ, Chen X et al (2000) The LIM and SH3 domain-containing protein, lasp-1, may link the cAMP signaling pathway with dynamic membrane restructuring activities in ion transporting epithelia. J Cell Sci 113:2035–2045PubMed

Chew CS, Chen X, Parente JJ et al (2002) Lasp-1 binds to non-muscle F-actin in vitro and is localized within multiple sites of dynamic actin assembly in vivo. J Cell Sci 115:4787–4799PubMedCrossRef

Chiyomaru T, Enokida H, Kawakami K et al (2012) Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol Oncol 30:434–443PubMedCrossRef

Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20PubMedCrossRef

Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917PubMedCrossRef

Grunewald TG, Kammerer U, Schulze E et al (2006) Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp Cell Res 312:974–982PubMedCrossRef

Grunewald TG, Kammerer U, Winkler C et al (2007) Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br J Cancer 96:296–305PubMedCrossRefPubMedCentral

Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127:679–695PubMedCrossRef

Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef

Nakagawa H, Terasaki AG, Suzuki H et al (2006) Short-term retention of actin filament binding proteins on lamellipodial actin bundles. FEBS Lett 580:3223–3228PubMedCrossRef

Rachlin AS, Otey CA (2006) Identification of palladin isoforms and characterization of an isoform-specific interaction between Lasp-1 and palladin. J Cell Sci 119:995–1004PubMedCrossRef

Salvi A, Bongarzone I, Micciche F et al (2009) Proteomic identification of LASP-1 down-regulation after RNAi urokinase silencing in human hepatocellular carcinoma cells. Neoplasia 11:207–219PubMedPubMedCentral

Tomasetto C, Moog-Lutz C, Regnier CH et al (1995) Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains. FEBS Lett 373:245–249PubMedCrossRef

Traenka C, Remke M, Korshunov A et al (2010) Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Cancer Res 70:8003–8014PubMedCrossRef

Wang B, Feng P, Xiao Z et al (2009) LIM and SH3 protein 1 (Lasp1) is a novel p53 transcriptional target involved in hepatocellular carcinoma. J Hepatol 50:528–537PubMedCrossRef

Wang H, Li W, Jin X et al (2013) LIM and SH3 protein 1, a promoter of cell proliferation and migration, is a novel independent prognostic indicator in hepatocellular carcinoma. Eur J Cancer 49:974–983PubMedCrossRef

Yu S, Zheng J, Jiang Z et al (2013) Protective effect of N-acetylserotonin against acute hepatic ischemia-reperfusion injury in mice. Int J Mol Sci 14:17680–17693PubMedCrossRefPubMedCentral

Zhao L, Wang H, Liu C et al (2010) Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1. Gut 59:1226–1235PubMedCrossRef

Title: LASP-1 promotes tumor proliferation and metastasis and is an independent unfavorable prognostic factor in gastric cancer
Publication date: 01-11-2014
Published in: Journal of Cancer Research and Clinical Oncology / Issue 11/2014
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1759-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

LASP-1 promotes tumor proliferation and metastasis and is an independent unfavorable prognostic factor in gastric cancer

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2014

Aberrant methylation of the MSH3 promoter and distal enhancer in esophageal cancer patients exposed to first-hand tobacco smoke

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase

Onco-epidemiology of domestic animals and targeted therapeutic attempts: perspectives on human oncology

Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis

Erratum to: Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis

A phase II study of radiofrequency ablation therapy for thoracic malignancies with evaluation by FDG-PET

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page